Related Experiment Videos
[ACE inhibition with cilazapril. Major therapeutic aspects: hypertension and metabolic syndrome]
1Medizinische Abteilung, Krankenhaus München-Perlach.
Insights
Essential hypertension and type II diabetes, often seen together as metabolic syndrome, strain the cardiovascular system. New research highlights ACE-inhibitors, like cilazapril, as effective treatments for hypertension, even with metabolic syndrome.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Context:
- Essential hypertension is genetically linked to disordered glucose metabolism, forming metabolic syndrome.
- Both hypertension and type II diabetes impose chronic stress on the heart and vasculature.
- Antihypertensive treatments aim to prevent vascular damage and reverse existing organic changes.
Purpose:
- To discuss the role of ACE-inhibitors in managing hypertension and associated vascular changes.
- To introduce cilazapril as a new ACE-inhibitor for treating hypertension.
- To evaluate cilazapril's efficacy in hypertensive patients with and without metabolic syndrome.
Summary:
- ACE-inhibitors are potent in managing hypertension-associated cardiovascular changes without increasing arteriosclerosis risk.
- Cilazapril is a novel ACE-inhibitor offering a practical single-dose administration.
- Cilazapril demonstrates a typical ACE-inhibitor action profile in hypertensive individuals, irrespective of metabolic syndrome presence.
Impact:
- Provides insights into managing complex cardiovascular and metabolic conditions.
- Highlights cilazapril as a promising therapeutic option for hypertension.
- Supports the use of ACE-inhibitors in patients with comorbid hypertension and metabolic syndrome.
Abstract:
Today, essential hypertension is considered to be genetically closely related to disordered peripheral glucose metabolism, and this situation is described by the term metabolic syndrome. Both diseases--hypertension and type II diabetes--submit the heart and arterial vessels to an unphysiological, chronic stress, which they can compensate only for a certain time. Today, when antihypertensive treatment is indicated, drugs capable of preventing late vascular injury while at the same time having the potency to reverse already existing organic changes, are employed. ACE-inhibitors are presently considered to be the most potent substances that are capable of exerting a positive effect on hypertension-associated changes, while not increasing the individual risk profile in the development of arteriosclerosis. The present paper discusses the new ACE-inhibitor, cilazapril, which can be administered in a practical single dose and develops a profile of action typical of ACE-inhibitors in hypertensives with and without an accompanying metabolic syndrome.